TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
20 12 2020
20 12 2020
Historique:
pubmed:
30
10
2020
medline:
16
3
2021
entrez:
29
10
2020
Statut:
ppublish
Résumé
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) in germline (g) Eligible patients had MBC with measurable disease and germline mutations in non- Fifty-four patients enrolled. Seventy-six percent had estrogen receptor-positive HER2-negative disease. Eighty-seven percent had mutations in PARP inhibition is an effective treatment for patients with MBC and g
Identifiants
pubmed: 33119476
doi: 10.1200/JCO.20.02151
doi:
Substances chimiques
Phthalazines
0
Piperazines
0
Poly(ADP-ribose) Polymerase Inhibitors
0
olaparib
WOH1JD9AR8
Banques de données
ClinicalTrials.gov
['NCT03344965']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM